CLINICAL TRIALS PROFILE FOR XOLAIR

Biosimilar Clinical Trials for XOLAIR

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05053334 ↗	Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair	Not yet recruiting	CuraTeQ Biologics Private Ltd.	Phase 1	2021-11-01	A single dose, double blind comparative trial to assess the pharmacokinetics, pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and EU-Xolair) containing 150mg of Omalizumab as subcutaneous injection in healthy male volunteers.
NCT05053334 ↗	Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair	Not yet recruiting	Syneos Health	Phase 1	2021-11-01	A single dose, double blind comparative trial to assess the pharmacokinetics, pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and EU-Xolair) containing 150mg of Omalizumab as subcutaneous injection in healthy male volunteers.

All Clinical Trials for XOLAIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00084097 ↗	Omalizumab to Treat Eosinophilic Gastroenteritis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2004-06-02	This study will evaluate the safety and usefulness of omalizumab (anti-IgE, Xolair) in reducing eosinophil counts and improving symptoms in patients with eosinophilic gastroenteritis (EG). EG is a disorder of unknown cause in which eosinophils, a type of white blood cell, are increased in the blood and gut tissue. Patients with EG have symptoms like stomach pain, bloating, and vomiting. About 50 percent of EG patients have food or environmental allergies, which may play a role in EG. Some patients with EG improve significantly on diets avoiding foods to which they are allergic. Immunoglobulin E (IgE) is an antibody that plays an important role in initiating allergic reactions. Omalizumab is a monoclonal antibody directed against IgE. The Food and Drug Administration approved omalizumab in 2003 for treating patients 12 years of age and older with allergic asthma. Patients between 12 and 76 years of age with eosinophilic gastroenteritis who have a blood eosinophil count of 500 or more and who have a food allergy or allergy to an inhaled allergen may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests. Participants undergo the following procedures: - Leukapheresis. This procedure is done to collect quantities of white blood cells to study the effects of omalizumab on eosinophils and other immune substances. Blood flows from a needle placed in an arm vein through a catheter (plastic tube) into a machine that separates the blood into its components by centrifugation (spinning). Some of the white cells are removed and the rest of the blood (red cells, plasma and platelets) is returned to the body through a needle in the other arm. - Skin testing. Participants are tested for allergies to specific substances. A small amount of various allergens (substances that cause allergies) are placed on the subject's arm. The skin is pricked at the sites of the allergens and the skin reaction after several minutes is observed. - Upper and lower endoscopy. One or both of these procedures is done, depending on the part of the gastrointestinal tract that is involved, to examine the tract. If both procedures are done, they are performed at the same time. For the upper endoscopy, the subject's throat is sprayed with a numbing medicine and a long, flexible tube is passed through the esophagus, stomach and small intestine. For the lower endoscopy, the tube is passed through the rectum into t...
NCT00086606 ↗	A Safety and Efficacy Study of Xolair in Peanut Allergy	Terminated	Genentech, Inc.	Phase 2	2004-06-01	This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
NCT00096954 ↗	A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)	Completed	Genentech, Inc.	Phase 4	2006-02-01	This was a multicenter, parallel-group, double-blind, randomized, placebo-controlled study that enrolled 333 subjects. These subjects were 12-75 years old with atopic asthma, had elevated serum total Immunoglobulin E (IgE), had a baseline forced expiratory volume in 1 second (FEV1) ≥ 80% predicted, and were on inhaled corticosteroids with or without other controller asthma medications (e.g., long-acting β2-agonists [LABAs], leukotriene receptor antagonist [LTRA], or immunotherapy).
NCT00109187 ↗	An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g	Completed	Genentech, Inc.	Phase 3	2002-06-01	This is a Phase IIIb, multicenter, open-label, extension study available to subjects who successfully complete Study Q2143g and have not participated in Study Q2195g. Subjects should be registered via the IVRS (Interactive Voice Response System) within 48 hours prior to their baseline visit. All subjects in this study will be treated with Xolair for 24 weeks. Subjects in the New Treatment Group may require additional visits for study drug injections (as frequently as every 2 weeks). Data collection during these additional visits will be limited to the assessment of adverse events. The study will evaluate all serious and nonserious adverse events, laboratory assessments, data on asthma exacerbations, and concomitant medication usage.
NCT00109200 ↗	A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma	Completed	Genentech, Inc.	Phase 3	2003-05-01	This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment. Subject eligibility will be based on disease severity and asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was
NCT00117611 ↗	Xolair in Patients With Chronic Sinusitis	Completed	Genentech, Inc.	Phase 4	2005-07-01	The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.

Clinical Trial Conditions for XOLAIR

Condition Name

Condition Name for XOLAIR
Intervention	Trials
Asthma	29
Food Allergy	9
Chronic Idiopathic Urticaria	8
Peanut Allergy	6

Condition MeSH

Condition MeSH for XOLAIR
Intervention	Trials
Asthma	34
Urticaria	19
Chronic Urticaria	16
Hypersensitivity	14

Clinical Trial Locations for XOLAIR

Trials by Country

Trials by Country for XOLAIR
Location	Trials
United States	353
China	31
Ukraine	19
Canada	16
Germany	14

Trials by US State

Trials by US State for XOLAIR
Location	Trials
California	25
Maryland	22
New York	16
Colorado	14
Massachusetts	13

Clinical Trial Progress for XOLAIR

Clinical Trial Phase

Clinical Trial Phase for XOLAIR
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 4	38

Clinical Trial Status

Clinical Trial Status for XOLAIR
Clinical Trial Phase	Trials
Completed	74
Not yet recruiting	8
Recruiting	8

Clinical Trial Sponsors for XOLAIR

Sponsor Name

Sponsor Name for XOLAIR
Sponsor	Trials
Genentech, Inc.	35
Novartis Pharmaceuticals	17
Novartis	14

Sponsor Type

Sponsor Type for XOLAIR
Sponsor	Trials
Other	95
Industry	82
NIH	16

Last updated: April 28, 2026

XOLAIR (omalizumab) | Clinical-Stage Update, Market Analysis, and Revenue Projection (2024-2035)

What is XOLAIR’s current clinical and regulatory trajectory?

XOLAIR (omalizumab) is an anti-IgE monoclonal antibody with broad label coverage in asthma and chronic spontaneous urticaria (CSU), and expanded use in allergic conditions in multiple geographies. The current market is driven by already-approved indications rather than a single late-stage “make-or-break” program.

Latest publicly disclosed late-stage development signals (2022-2024)

• XOLAIR has continued to add indication/label detail in multiple jurisdictions, and the development program has remained active across asthma phenotypes and allergic disease subpopulations.
• Across the class (anti-IgE), ongoing work typically targets: (1) earlier lines of care, (2) pediatric down-titration, and (3) biomarker-refined responders (IgE levels, eosinophils, fractional exhaled nitric oxide, exacerbation history).
• No single, widely public late-stage readout in 2023-2024 has displaced the commercial center of gravity, which stays with established indications and ongoing renewals in current prescribers.

Regulatory “lifecycle” implication

• XOLAIR’s near-to-mid term value is tied more to label maintenance and incremental regimen optimization than to a single new pivotal approval that would create a step-change in total addressable population.

Clinical trial update (structure)

• Asthma: trials and postmarketing studies have continued to address dosing, persistence, exacerbation reduction, and biomarker-defined use in allergic asthma.
• CSU: real-world durability, dose adjustments, and positioning versus oral antihistamines/biologics or step-care approaches remain active themes.

Source: XOLAIR prescribing information and label histories in major markets. [1], [2]

---

What is the current market footprint for XOLAIR (global and indication-driven)?

XOLAIR’s commercial demand is concentrated in: 1) Moderate-to-severe allergic asthma (adult and pediatric populations, with IgE- and weight-based dosing), 2) Chronic spontaneous urticaria in patients inadequately controlled with H1 antihistamines.

Commercial drivers

• High persistence for responders: the therapy’s value is assessed by exacerbation reduction (asthma) and hive/itch control (CSU), typically supporting repeat use and steady prescribing.
• Biomarker-guided positioning: IgE-based dosing supports payer coverage logic in many markets.
• Geographic penetration: uptake expands where biologic pathway access, reimbursement, and specialist density are strongest.

Key constraints

• Biosimilar and competitive intensity: class competition in asthma and urticaria continues (anti-IL5/IL4R, anti-IgE/anti-TSLP adjacent strategies, and newer CSU biologics in certain markets).
• Utilization ceilings tied to eligible patients: IgE/weight criteria for dosing constrain pool size in asthma.

Source: global label and clinical use framework in asthma and CSU. [1], [2]

---

How large is the addressable market, and what share can XOLAIR realistically capture?

A practical way to model XOLAIR market share is to anchor demand to eligible treated populations in asthma and CSU plus therapy persistence and dose intensity.

Market sizing logic (model inputs)

• Eligible asthma pool: allergic asthma with uncontrolled symptoms/exacerbation history despite standard therapy; dosing requires IgE and weight parameters aligned with XOLAIR regimens. [1]
• CSU pool: antihistamine-refractory CSU requiring biologic escalation; includes patients who meet guideline thresholds for nonresponse/intolerance. [2]
• Adoption curve: incremental adoption stabilizes after initial diffusion; subsequent growth comes from net new prescribers, expanded label interpretation, and improved pathway access.

Share capture assumptions (commercially conservative)

• XOLAIR retains a meaningful share in allergic asthma because it is established and prescriber-friendly where IgE-guided dosing aligns with existing reimbursement criteria.
• In CSU, XOLAIR remains a core option but competes against newer mechanistic entrants depending on country-specific payer preferences and patient response durability.

Source: label-based positioning and indication frameworks. [1], [2]

---

What is the revenue projection for XOLAIR from 2024 to 2035?

Below is a scenario-based projection designed for investment and R&D portfolio planning. It assumes no abrupt class disruption (no sudden biosimilar erosion in the base years) and models a typical late-cycle biologic pattern: steady growth from utilization and penetration early in the projection window, followed by plateau and gradual decline or slower growth depending on competitive dynamics.

Base-case revenue projection (global)

Assumptions embedded

• Mid-single-digit volume growth in early years from penetration and dosing persistence.
• Low-to-mid single-digit price erosion offset partially by mix and persistence.
• Competition dampens growth rate after the midpoint of the projection.

Projected revenue range (global)	Year	Revenue (USD, global)	Growth vs prior year
2024	3.9 - 4.4B	-
2025	4.1 - 4.6B	+2% to +5%
2026	4.2 - 4.8B	+2% to +6%
2027	4.3 - 4.9B	+1% to +4%
2028	4.3 - 4.9B	-1% to +2%
2029	4.2 - 4.8B	-2% to +1%
2030	4.1 - 4.7B	-2% to -1%
2031	4.0 - 4.6B	-2% to 0%
2032	3.9 - 4.5B	-2% to 0%
2033	3.8 - 4.4B	-2% to 0%
2034	3.7 - 4.3B	-2% to 0%
2035	3.6 - 4.2B	-2% to 0%

Interpretation for decision-makers

• The most bankable value driver is maintenance of allergic asthma share and persistence in CSU where XOLAIR remains a reimbursed option.
• The projection expects growth to slow after 2027 due to competitive displacement and payer pressure, with decline limited by ongoing label utility and patient-level repeat use.

Source: dosing and indication scope from XOLAIR prescribing information; pricing dynamics framework consistent with biologic late-cycle patterns. [1], [2]

---

What are the key competitive and clinical risks to the projection?

Competitive risks

• Mechanism-based displacement in asthma and CSU could reduce net new starts or shift patients to alternative biologics depending on biomarker fit and payer pathways.
• In CSU, newer options can tighten access for established biologics based on local reimbursement policies.

Clinical risks

• Broad label populations can erode if payer restricts eligibility using real-world response criteria (exacerbation reduction thresholds, symptom control metrics).
• Any evidence shifts in guidelines toward different step-care ordering can reduce new starts.

Source: XOLAIR indications and use restrictions tied to asthma severity and CSU antihistamine-refractory criteria. [1], [2]

---

Which R&D moves matter most for XOLAIR’s next value window?

Given the late-cycle profile, the highest-leverage development is typically:

• Responder stratification refinement (better identification of IgE/biomarker profiles with best response),
• Dosing optimization and regimen simplification that reduces adherence friction and lowers discontinuation,
• Real-world evidence generation to support payer criteria and formulary access,
• Expanded pediatric clarity where label updates expand eligibility or improve dosing confidence.

Source: clinical use model and dosing framework from label. [1], [2]

---

Market outlook by indication (what to watch)

Asthma

Watchpoints:

• Persistence and exacerbation reduction outcomes that support continuation.
• Payer controls tied to step-therapy access.
• Any guideline shifts affecting use of biologics versus other controller regimens.

CSU

Watchpoints:

• Rate of biologic switching and payer preference changes.
• Duration of response metrics and dose adjustment patterns in real-world settings.
• Patient selection improvements that maintain response durability.

Source: label-based indication descriptions and dosing logic. [1], [2]

---

Key Takeaways

• XOLAIR’s growth profile in the 2024-2035 window is driven primarily by persistence and penetration within established asthma and CSU indications, not by a single late-stage “breakout” approval.
• The base-case global revenue trajectory projects slow growth into the late 2020s and gradual plateau-to-decline thereafter, reflecting competitive pressure and payer tightening.
• The investment-relevant risk is share erosion from competing biologics and reimbursement restrictions, especially where real-world response thresholds become gatekeeping criteria.
• The commercial lever with the highest impact remains maintaining responder identification and continuation rates through clinical and real-world evidence tied to label dosing logic.

---

FAQs

1. Is XOLAIR still primarily a biologic for asthma and chronic spontaneous urticaria?
   Yes. Its core commercial indications remain allergic asthma and CSU under IgE-based and antihistamine-refractory frameworks in major labels. [1], [2]

2. What drives XOLAIR dosing decisions in asthma?
   Dosing is based on patient weight and baseline IgE levels within the label dosing table. [1]

3. What is the biggest commercial risk for XOLAIR?
   Competitive displacement by other asthma and CSU biologics and payer restrictions that tighten eligibility. [1], [2]

4. Does XOLAIR’s clinical value translate into persistence?
   In practice, patients who respond to symptom or exacerbation control tend to continue, supporting stability for established prescribers, subject to payer criteria and discontinuation for nonresponse. [1], [2]

5. How should the 2024-2035 forecast be used for planning?
   Use it to stress-test portfolio cash flows under late-cycle biologic dynamics: modest early growth, plateau, then gradual soft decline depending on market access and competitive intensity. [1], [2]

---

References

[1] Novartis Pharmaceuticals Corporation. (n.d.). XOLAIR (omalizumab) prescribing information.
[2] European Medicines Agency. (n.d.). XOLAIR (omalizumab) product information / EPAR.